VISTARIL (hydroxyzine hydrochloride) by Pfizer is clinical pharmacology hydroxyzine hydrochloride is unrelated chemically to the phenothiazines, reserpine, meprobamate or the benzodiazepines. Approved for anxiety. First approved in 1957.
Drug data last refreshed 3h ago · AI intelligence enriched 3w ago
VISTARIL (hydroxyzine hydrochloride) is a small-molecule anxiolytic approved in 1957 for the treatment of anxiety. It works by suppressing activity in key subcortical regions of the central nervous system and has demonstrated antihistaminic, bronchodilator, analgesic, and antiemetic properties. The drug is administered via injection and exhibits clinical effects within 15-30 minutes of administration.
Declining revenue profile with LOE approaching signals reduced team investment and focus on generic defense or market exit strategies.
CLINICAL PHARMACOLOGY Hydroxyzine hydrochloride is unrelated chemically to the phenothiazines, reserpine, meprobamate or the benzodiazepines. Hydroxyzine is not a cortical depressant, but its action may be due to a suppression of activity in certain key regions of the subcortical area of the…
Does Preventive Analgesia Improve the Outcome of Demerol-Vistaril Procedural Sedations in Pediatric Dentistry
Worked on VISTARIL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moVISTARIL represents a career profile focused on mature product stewardship and LOE transition management rather than growth. Opportunities exist in generic defense, market access strategy, and commercial optimization, but team size and investment are declining.